Epidiolex

Overview

cannabidiol

cannabinoid

• CYP2C19 substrate
• CYP3A4 substrate
• CYP1A2 inhibitor, weak
• CYP2B6 inhibitor, weak
• CYP2C8 inhibitor, weak
• CYP2C9 inhibitor, weak
• CYP2C19 inhibitor, moderate
• UGT1A9 inhibitor
• UGT2B7 inhibitor
• P-gp inhibitor, strong
• CYP2B6 inducer, weak
• affected by altered fat absorption
• antiepileptic agent
• CNS depression

Contraindicated

• amifampridine
Epidiolex (cannabidiol (CBD))

+

amifampridine

1 interaction

Contraindicated

cannabidiol + amifampridine

contraindicated: combo may alter seizure control (antagonistic effects, amifampridine may decr. seizure threshold)

• bupropion
Epidiolex (cannabidiol (CBD))

+

bupropion

1 interaction

Contraindicated

cannabidiol + bupropion

contraindicated: combo may incr. or decr. bupropion levels, incr. risk of seizures, other adverse effects or decr. active metabolite levels, efficacy (hepatic metab. possibly altered; antagonistic effects, bupropion may decr. seizure threshold)

• colchicine
Epidiolex (cannabidiol (CBD))

+

colchicine

1 interaction

Contraindicated

cannabidiol + colchicine

CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, decr. colchicine dose based on indication during and x14 days after cannabidiol use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (gut P-gp-mediated transport inhibited)

• dalfampridine
Epidiolex (cannabidiol (CBD))

+

dalfampridine

1 interaction

Contraindicated

cannabidiol + dalfampridine

contraindicated: combo may alter seizure control (antagonistic effects, dalfampridine may decr. seizure threshold)

• fezolinetant
Epidiolex (cannabidiol (CBD))

+

fezolinetant

1 interaction

Contraindicated

cannabidiol + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metab. inhibited)

Avoid/Use Alternative

• abrocitinib
Epidiolex (cannabidiol (CBD))

+

abrocitinib

1 interaction

Avoid/Use Alternative

cannabidiol + abrocitinib

avoid combo if also combined w/ moderate or strong CYP2C9 inhibitor; otherwise, caution advised: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, other adverse effects (hepatic metab. inhibited)

• apixaban
Epidiolex (cannabidiol (CBD))

+

apixaban

1 interaction

Avoid/Use Alternative

cannabidiol + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• bosentan
Epidiolex (cannabidiol (CBD))

+

bosentan

1 interaction

Avoid/Use Alternative

cannabidiol + bosentan

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise caution advised: combo may incr. bosentan levels, risk of adverse effects; may decr. cannabidiol levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• butalbital
Epidiolex (cannabidiol (CBD))

+

butalbital

1 interaction

Avoid/Use Alternative

cannabidiol + butalbital

avoid combo: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• cannabis
Epidiolex (cannabidiol (CBD))

+

cannabis

1 interaction

Avoid/Use Alternative

cannabidiol + cannabis

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (additive effects, duplicate tx; antagonistic effects, cannabis may decr. seizure threshold)

• clonidine
Epidiolex (cannabidiol (CBD))

+

clonidine

1 interaction

Avoid/Use Alternative

cannabidiol + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clopidogrel
Epidiolex (cannabidiol (CBD))

+

clopidogrel

1 interaction

Avoid/Use Alternative

cannabidiol + clopidogrel

avoid combo: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metab. inhibited, decr. conversion of clopidogrel to active metabolite)

• codeine
Epidiolex (cannabidiol (CBD))

+

codeine

1 interaction

Avoid/Use Alternative

cannabidiol + codeine

avoid combo if antitussive use; otherwise monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, codeine may decr. seizure threshold)

• dabigatran
Epidiolex (cannabidiol (CBD))

+

dabigatran

1 interaction

Avoid/Use Alternative

cannabidiol + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (incl. life-threatening), other adverse effects (gut P-gp-mediated transport inhibited)

• doxylamine
Epidiolex (cannabidiol (CBD))

+

doxylamine

1 interaction

Avoid/Use Alternative

cannabidiol + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ensartinib
Epidiolex (cannabidiol (CBD))

+

ensartinib

1 interaction

Avoid/Use Alternative

cannabidiol + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• ethanol
Epidiolex (cannabidiol (CBD))

+

ethanol

1 interaction

Avoid/Use Alternative

cannabidiol + ethanol

avoid combo: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• futibatinib
Epidiolex (cannabidiol (CBD))

+

futibatinib

1 interaction

Avoid/Use Alternative

cannabidiol + futibatinib

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (gut P-gp-mediated transport inhibited)

• ginkgo
Epidiolex (cannabidiol (CBD))

+

ginkgo

1 interaction

Avoid/Use Alternative

cannabidiol + ginkgo

avoid consumption of ginkgo seeds; otherwise, caution advised: combo may alter seizure control (antagonistic effects, ginkgotoxin may decr. seizure threshold)

• hydrocodone
Epidiolex (cannabidiol (CBD))

+

hydrocodone

1 interaction

Avoid/Use Alternative

cannabidiol + hydrocodone

avoid combo if antitussive use; otherwise monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydrocodone may decr. seizure threshold)

• isocarboxazid
Epidiolex (cannabidiol (CBD))

+

isocarboxazid

1 interaction

Avoid/Use Alternative

cannabidiol + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, isocarboxazid may decr. seizure threshold)

• kava
Epidiolex (cannabidiol (CBD))

+

kava

1 interaction

Avoid/Use Alternative

cannabidiol + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• kratom
Epidiolex (cannabidiol (CBD))

+

kratom

1 interaction

Avoid/Use Alternative

cannabidiol + kratom

use alternative or monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, kratom may decr. seizure threshold)

• lefamulin
Epidiolex (cannabidiol (CBD))

+

lefamulin

1 interaction

Avoid/Use Alternative

cannabidiol + lefamulin

ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• lenacapavir
Epidiolex (cannabidiol (CBD))

+

lenacapavir

1 interaction

Avoid/Use Alternative

cannabidiol + lenacapavir

avoid combo w/ oral lenacapavir if also combined w/ strong CYP3A4 and UGT1A1 inhibitors; otherwise, caution advised: combo may incr. lenacapavir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• lorazepam
Epidiolex (cannabidiol (CBD))

+

lorazepam

1 interaction

Avoid/Use Alternative

cannabidiol + lorazepam

avoid combo w/ lorazepam ER; monitor resp. rate and consider decr. lorazepam IR or INJ dose; use lowest effective doses and shortest duration of concomitant tx: combo may incr. lorazepam levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

• meperidine
Epidiolex (cannabidiol (CBD))

+

meperidine

1 interaction

Avoid/Use Alternative

cannabidiol + meperidine

use alternative or monitor resp. rate, ECG, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. or decr. meperidine levels, incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy, may incr. normeperidine levels, risk of neurotoxicity; may alter seizure control (hepatic metab. possibly inhibited; hepatic metab. possibly induced, incr. toxic metabolite formation; additive effects; antagonistic effects, meperidine may decr. seizure threshold)

• metaxalone
Epidiolex (cannabidiol (CBD))

+

metaxalone

1 interaction

Avoid/Use Alternative

cannabidiol + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methadone
Epidiolex (cannabidiol (CBD))

+

methadone

1 interaction

Avoid/Use Alternative

cannabidiol + methadone

use alternative or monitor resp. rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. or decr. methadone levels, incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy; may alter seizure control (hepatic metab. inhibited, hepatic metab. possibly induced; additive effects; antagonistic effects, methadone may decr. seizure threshold)

• metoclopramide
Epidiolex (cannabidiol (CBD))

+

metoclopramide

1 interaction

Avoid/Use Alternative

cannabidiol + metoclopramide

use alternative: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, metoclopramide may decr. seizure threshold; additive effects)

• midazolam
Epidiolex (cannabidiol (CBD))

+

midazolam

1 interaction

Avoid/Use Alternative

cannabidiol + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• neratinib
Epidiolex (cannabidiol (CBD))

+

neratinib

1 interaction

Avoid/Use Alternative

cannabidiol + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• norgestimate (contraceptive)
Epidiolex (cannabidiol (CBD))

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

cannabidiol + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after cannabidiol tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metab. possibly induced)

• oxybate
Epidiolex (cannabidiol (CBD))

+

oxybate

1 interaction

Avoid/Use Alternative

cannabidiol + oxybate

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• pazopanib
Epidiolex (cannabidiol (CBD))

+

pazopanib

1 interaction

Avoid/Use Alternative

cannabidiol + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• phenelzine
Epidiolex (cannabidiol (CBD))

+

phenelzine

1 interaction

Avoid/Use Alternative

cannabidiol + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, phenelzine may decr. seizure threshold)

• pirfenidone
Epidiolex (cannabidiol (CBD))

+

pirfenidone

1 interaction

Avoid/Use Alternative

cannabidiol + pirfenidone

avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• pralsetinib
Epidiolex (cannabidiol (CBD))

+

pralsetinib

1 interaction

Avoid/Use Alternative

cannabidiol + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• promethazine
Epidiolex (cannabidiol (CBD))

+

promethazine

1 interaction

Avoid/Use Alternative

cannabidiol + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, promethazine may decr. seizure threshold)

• relugolix
Epidiolex (cannabidiol (CBD))

+

relugolix

1 interaction

Avoid/Use Alternative

cannabidiol + relugolix

PROSTATE CANCER: may hold relugolix if oral cannabidiol tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral cannabidiol; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral cannabidiol: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• repotrectinib
Epidiolex (cannabidiol (CBD))

+

repotrectinib

1 interaction

Avoid/Use Alternative

cannabidiol + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, adverse effects; may decr. cannabidiol levels, efficacy (gut P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• rivaroxaban
Epidiolex (cannabidiol (CBD))

+

rivaroxaban

1 interaction

Avoid/Use Alternative

cannabidiol + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• ropeginterferon alfa-2b
Epidiolex (cannabidiol (CBD))

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

cannabidiol + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• silodosin
Epidiolex (cannabidiol (CBD))

+

silodosin

1 interaction

Avoid/Use Alternative

cannabidiol + silodosin

avoid combo: combo may incr. silodosin levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• thalidomide
Epidiolex (cannabidiol (CBD))

+

thalidomide

1 interaction

Avoid/Use Alternative

cannabidiol + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thalidomide may decr. seizure threshold)

• tizanidine
Epidiolex (cannabidiol (CBD))

+

tizanidine

1 interaction

Avoid/Use Alternative

cannabidiol + tizanidine

use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (incl. orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• topotecan
Epidiolex (cannabidiol (CBD))

+

topotecan

1 interaction

Avoid/Use Alternative

cannabidiol + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• tranylcypromine
Epidiolex (cannabidiol (CBD))

+

tranylcypromine

1 interaction

Avoid/Use Alternative

cannabidiol + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tranylcypromine may decr. seizure threshold)

• venetoclax
Epidiolex (cannabidiol (CBD))

+

venetoclax

1 interaction

Avoid/Use Alternative

cannabidiol + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• zuranolone
Epidiolex (cannabidiol (CBD))

+

zuranolone

1 interaction

Avoid/Use Alternative

cannabidiol + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• afatinib
Epidiolex (cannabidiol (CBD))

+

afatinib

1 interaction

Monitor/Modify Tx

cannabidiol + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• aldesleukin
Epidiolex (cannabidiol (CBD))

+

aldesleukin

1 interaction

Monitor/Modify Tx

cannabidiol + aldesleukin

withhold aldesleukin if mod-severe somnolence occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aldesleukin may decr. seizure threshold)

• alfentanil
Epidiolex (cannabidiol (CBD))

+

alfentanil

1 interaction

Monitor/Modify Tx

cannabidiol + alfentanil

monitor BP, resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, alfentanil may decr. seizure threshold)

• alprazolam
Epidiolex (cannabidiol (CBD))

+

alprazolam

1 interaction

Monitor/Modify Tx

cannabidiol + alprazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• aminophylline
Epidiolex (cannabidiol (CBD))

+

aminophylline

1 interaction

Monitor/Modify Tx

cannabidiol + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities; may alter seizure control (hepatic metab. inhibited; aminophylline converted to theophylline; antagonistic effects, theophylline may decr. seizure threshold)

• amiodarone
Epidiolex (cannabidiol (CBD))

+

amiodarone

1 interaction

Monitor/Modify Tx

cannabidiol + amiodarone

monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. possibly inhibited)

• apalutamide
Epidiolex (cannabidiol (CBD))

+

apalutamide

1 interaction

Monitor/Modify Tx

cannabidiol + apalutamide

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, apalutamide may decr. seizure threshold)

• atorvastatin
Epidiolex (cannabidiol (CBD))

+

atorvastatin

1 interaction

Monitor/Modify Tx

cannabidiol + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited)

• avatrombopag
Epidiolex (cannabidiol (CBD))

+

avatrombopag

1 interaction

Monitor/Modify Tx

cannabidiol + avatrombopag

monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (gut P-gp-mediated transport inhibited)

• baclofen intrathecal
Epidiolex (cannabidiol (CBD))

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

cannabidiol + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, baclofen may decr. seizure threshold)

• belzutifan
Epidiolex (cannabidiol (CBD))

+

belzutifan

1 interaction

Monitor/Modify Tx

cannabidiol + belzutifan

monitor Hgb, hypoxia s/sx: combo may incr. belzutifan levels, risk of anemia, hypoxia, other adverse effects (hepatic metab. inhibited)

• bendamustine
Epidiolex (cannabidiol (CBD))

+

bendamustine

1 interaction

Monitor/Modify Tx

cannabidiol + bendamustine

monitor CBC: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• buprenorphine
Epidiolex (cannabidiol (CBD))

+

buprenorphine

1 interaction

Monitor/Modify Tx

cannabidiol + buprenorphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, buprenorphine may decr. seizure threshold)

• butorphanol
Epidiolex (cannabidiol (CBD))

+

butorphanol

1 interaction

Monitor/Modify Tx

cannabidiol + butorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, butorphanol may decr. seizure threshold)

• caffeine citrate
Epidiolex (cannabidiol (CBD))

+

caffeine citrate

1 interaction

Monitor/Modify Tx

cannabidiol + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metab. inhibited)

• carbamazepine
Epidiolex (cannabidiol (CBD))

+

carbamazepine

1 interaction

Monitor/Modify Tx

cannabidiol + carbamazepine

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• carvedilol
Epidiolex (cannabidiol (CBD))

+

carvedilol

1 interaction

Monitor/Modify Tx

cannabidiol + carvedilol

monitor BP, HR: combo may incr. carvedilol levels, risk of hypotension, bradycardia, AV block, other adverse effects (gut P-gp-mediated transport inhibited)

• celecoxib
Epidiolex (cannabidiol (CBD))

+

celecoxib

1 interaction

Monitor/Modify Tx

cannabidiol + celecoxib

monitor bleeding s/sx: combo may incr. celecoxib levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• ceritinib
Epidiolex (cannabidiol (CBD))

+

ceritinib

1 interaction

Monitor/Modify Tx

cannabidiol + ceritinib

monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• chlordiazepoxide
Epidiolex (cannabidiol (CBD))

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

cannabidiol + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chlorpromazine
Epidiolex (cannabidiol (CBD))

+

chlorpromazine

1 interaction

Monitor/Modify Tx

cannabidiol + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, chlorpromazine may decr. seizure threshold)

• cilostazol
Epidiolex (cannabidiol (CBD))

+

cilostazol

1 interaction

Monitor/Modify Tx

cannabidiol + cilostazol

decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metab. inhibited)

• citalopram
Epidiolex (cannabidiol (CBD))

+

citalopram

1 interaction

Monitor/Modify Tx

cannabidiol + citalopram

adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited, additive effects; antagonistic effects, citalopram may decr. seizure threshold)

• clobazam
Epidiolex (cannabidiol (CBD))

+

clobazam

1 interaction

Monitor/Modify Tx

cannabidiol + clobazam

monitor resp. rate, ALT, AST, total bilirubin, ammonia levels, s/sx infection, D/C clobazam if liver enzyme elevations occur; consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of CNS and resp. depression, psychomotor impairment, hepatocellular injury, hyperammonemia, pneumonia, other adverse effects (hepatic metab. inhibited, additive effects)

• clonazepam
Epidiolex (cannabidiol (CBD))

+

clonazepam

1 interaction

Monitor/Modify Tx

cannabidiol + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clorazepate
Epidiolex (cannabidiol (CBD))

+

clorazepate

1 interaction

Monitor/Modify Tx

cannabidiol + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clozapine
Epidiolex (cannabidiol (CBD))

+

clozapine

1 interaction

Monitor/Modify Tx

cannabidiol + clozapine

monitor ECG, BP, HR; consider clozapine dose adjustment: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited; additive effects; antagonistic effects, clozapine may decr. seizure threshold)

• cyclophosphamide
Epidiolex (cannabidiol (CBD))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

cannabidiol + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. or decr. cyclophosphamide active metabolite levels, incr. risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other toxicities or decr. efficacy (hepatic metab. possibly altered, incr. or decr. active metabolite formation)

• cyclosporine
Epidiolex (cannabidiol (CBD))

+

cyclosporine

1 interaction

Monitor/Modify Tx

cannabidiol + cyclosporine

monitor oral cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, cyclosporine may decr. seizure threshold)

• daridorexant
Epidiolex (cannabidiol (CBD))

+

daridorexant

1 interaction

Monitor/Modify Tx

cannabidiol + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desflurane
Epidiolex (cannabidiol (CBD))

+

desflurane

1 interaction

Monitor/Modify Tx

cannabidiol + desflurane

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• deuruxolitinib
Epidiolex (cannabidiol (CBD))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

cannabidiol + deuruxolitinib

monitor CBC, thrombosis s/sx: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dexmedetomidine
Epidiolex (cannabidiol (CBD))

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

cannabidiol + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Epidiolex (cannabidiol (CBD))

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

cannabidiol + dexmedetomidine injection

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• diazepam
Epidiolex (cannabidiol (CBD))

+

diazepam

1 interaction

Monitor/Modify Tx

cannabidiol + diazepam

monitor resp. rate, use lowest effective doses and shortest duration of concomitant tx: combo may incr. diazepam levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• diclofenac
Epidiolex (cannabidiol (CBD))

+

diclofenac

1 interaction

Monitor/Modify Tx

cannabidiol + diclofenac

monitor bleeding s/sx; use lowest effective diclofenac dose, shortest duration of concomitant tx: combo may incr. diclofenac levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• digoxin
Epidiolex (cannabidiol (CBD))

+

digoxin

1 interaction

Monitor/Modify Tx

cannabidiol + digoxin

monitor oral digoxin levels, HR, and decr. oral digoxin frequency or dose by 30-50%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (gut P-gp-mediated transport inhibited)

• dihydrocodeine
Epidiolex (cannabidiol (CBD))

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

cannabidiol + dihydrocodeine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, dihydrocodeine may decr. seizure threshold)

• diltiazem
Epidiolex (cannabidiol (CBD))

+

diltiazem

1 interaction

Monitor/Modify Tx

cannabidiol + diltiazem

monitor BP, HR w/ oral diltiazem: combo may incr. diltiazem levels, risk of hypotension, bradycardia, AV block, other adverse effects (gut P-gp-mediated transport inhibited)

• droperidol
Epidiolex (cannabidiol (CBD))

+

droperidol

1 interaction

Monitor/Modify Tx

cannabidiol + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• edoxaban
Epidiolex (cannabidiol (CBD))

+

edoxaban

1 interaction

Monitor/Modify Tx

cannabidiol + edoxaban

monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• encorafenib
Epidiolex (cannabidiol (CBD))

+

encorafenib

1 interaction

Monitor/Modify Tx

cannabidiol + encorafenib

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• enzalutamide
Epidiolex (cannabidiol (CBD))

+

enzalutamide

1 interaction

Monitor/Modify Tx

cannabidiol + enzalutamide

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, enzalutamide may decr. seizure threshold)

• esketamine
Epidiolex (cannabidiol (CBD))

+

esketamine

1 interaction

Monitor/Modify Tx

cannabidiol + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• esomeprazole
Epidiolex (cannabidiol (CBD))

+

esomeprazole

1 interaction

Monitor/Modify Tx

cannabidiol + esomeprazole

consider decr. esomeprazole dose if dose >40 mg, especially if also combined w/ a CYP3A4 inhibitor: combo may incr. esomeprazole levels, risk of adverse effects (hepatic metab. inhibited)

• estazolam
Epidiolex (cannabidiol (CBD))

+

estazolam

1 interaction

Monitor/Modify Tx

cannabidiol + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Epidiolex (cannabidiol (CBD))

+

eszopiclone

1 interaction

Monitor/Modify Tx

cannabidiol + eszopiclone

consider dose reduction of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethanol (in some formulations)
Epidiolex (cannabidiol (CBD))

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

cannabidiol + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etomidate
Epidiolex (cannabidiol (CBD))

+

etomidate

1 interaction

Monitor/Modify Tx

cannabidiol + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etoposide
Epidiolex (cannabidiol (CBD))

+

etoposide

1 interaction

Monitor/Modify Tx

cannabidiol + etoposide

monitor CBC w/ oral etoposide: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• everolimus
Epidiolex (cannabidiol (CBD))

+

everolimus

1 interaction

Monitor/Modify Tx

cannabidiol + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, other adverse effects (gut P-gp-mediated transport inhibited)

• fedratinib
Epidiolex (cannabidiol (CBD))

+

fedratinib

1 interaction

Monitor/Modify Tx

cannabidiol + fedratinib

if also combined w/ moderate or weak CYP3A4 inhibitor, monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• fentanyl
Epidiolex (cannabidiol (CBD))

+

fentanyl

1 interaction

Monitor/Modify Tx

cannabidiol + fentanyl

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fentanyl may decr. seizure threshold)

• flibanserin
Epidiolex (cannabidiol (CBD))

+

flibanserin

1 interaction

Monitor/Modify Tx

cannabidiol + flibanserin

monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• fluphenazine
Epidiolex (cannabidiol (CBD))

+

fluphenazine

1 interaction

Monitor/Modify Tx

cannabidiol + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fluphenazine may decr. seizure threshold)

• flurazepam
Epidiolex (cannabidiol (CBD))

+

flurazepam

1 interaction

Monitor/Modify Tx

cannabidiol + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• fluvastatin
Epidiolex (cannabidiol (CBD))

+

fluvastatin

1 interaction

Monitor/Modify Tx

cannabidiol + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• fosphenytoin
Epidiolex (cannabidiol (CBD))

+

fosphenytoin

1 interaction

Monitor/Modify Tx

cannabidiol + fosphenytoin

monitor phenytoin levels; consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. phenytoin levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced; hepatic metab. inhibited, additive effects)

• gabapentin
Epidiolex (cannabidiol (CBD))

+

gabapentin

1 interaction

Monitor/Modify Tx

cannabidiol + gabapentin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Epidiolex (cannabidiol (CBD))

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

cannabidiol + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gilteritinib
Epidiolex (cannabidiol (CBD))

+

gilteritinib

1 interaction

Monitor/Modify Tx

cannabidiol + gilteritinib

monitor ECG: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• glimepiride
Epidiolex (cannabidiol (CBD))

+

glimepiride

1 interaction

Monitor/Modify Tx

cannabidiol + glimepiride

monitor glucose: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• hydromorphone
Epidiolex (cannabidiol (CBD))

+

hydromorphone

1 interaction

Monitor/Modify Tx

cannabidiol + hydromorphone

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydromorphone may decr. seizure threshold)

• hydroxyzine
Epidiolex (cannabidiol (CBD))

+

hydroxyzine

1 interaction

Monitor/Modify Tx

cannabidiol + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• idelalisib
Epidiolex (cannabidiol (CBD))

+

idelalisib

1 interaction

Monitor/Modify Tx

cannabidiol + idelalisib

monitor LFTs, CBC, GI toxicity sx: combo may incr. idelalisib levels, risk of hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (gut P-gp-mediated transport inhibited)

• ifosfamide
Epidiolex (cannabidiol (CBD))

+

ifosfamide

1 interaction

Monitor/Modify Tx

cannabidiol + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment; D/C one or both drugs if encephalopathy occurs: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, CNS depression, psychomotor impairment, cardiotoxicity, other adverse effects; may decr. ifosfamide active metabolite levels, efficacy; may alter seizure control (hepatic metab. possibly altered, incr. or decr. active metabolite formation; additive effects; antagonistic effects, ifosfamide may decr. seizure threshold)

• isoflurane
Epidiolex (cannabidiol (CBD))

+

isoflurane

1 interaction

Monitor/Modify Tx

cannabidiol + isoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ivosidenib
Epidiolex (cannabidiol (CBD))

+

ivosidenib

1 interaction

Monitor/Modify Tx

cannabidiol + ivosidenib

monitor ECG; consider cannabidiol dose adjustment: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. cannabidiol levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• ketamine
Epidiolex (cannabidiol (CBD))

+

ketamine

1 interaction

Monitor/Modify Tx

cannabidiol + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ketamine may decr. seizure threshold)

• lamotrigine
Epidiolex (cannabidiol (CBD))

+

lamotrigine

1 interaction

Monitor/Modify Tx

cannabidiol + lamotrigine

consider lamotrigine dose adjustment: combo may incr. lamotrigine levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

• lapatinib
Epidiolex (cannabidiol (CBD))

+

lapatinib

1 interaction

Monitor/Modify Tx

cannabidiol + lapatinib

monitor ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• lemborexant
Epidiolex (cannabidiol (CBD))

+

lemborexant

1 interaction

Monitor/Modify Tx

cannabidiol + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levorphanol
Epidiolex (cannabidiol (CBD))

+

levorphanol

1 interaction

Monitor/Modify Tx

cannabidiol + levorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, levorphanol may decr. seizure threshold)

• loperamide
Epidiolex (cannabidiol (CBD))

+

loperamide

1 interaction

Monitor/Modify Tx

cannabidiol + loperamide

monitor ECG, esp. if also combined w/ CYP3A4 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. possibly inhibited, gut P-gp-mediated transport inhibited)

• lovastatin
Epidiolex (cannabidiol (CBD))

+

lovastatin

1 interaction

Monitor/Modify Tx

cannabidiol + lovastatin

monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited)

• lumacaftor/ivacaftor
Epidiolex (cannabidiol (CBD))

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

cannabidiol + lumacaftor/ ivacaftor

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• mavacamten
Epidiolex (cannabidiol (CBD))

+

mavacamten

1 interaction

Monitor/Modify Tx

cannabidiol + mavacamten

monitor cardiac fxn, incl. LVEF; if pt stable on cannabidiol tx, initiate mavacamten at 2.5 mg qd; if adding short-term (<1wk) cannabidiol tx to existing mavacamten tx, hold mavacamten until cannabidiol D/C; if adding longer-term (>1wk) cannabidiol tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start cannabidiol tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. cannabidiol levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• mavorixafor
Epidiolex (cannabidiol (CBD))

+

mavorixafor

1 interaction

Monitor/Modify Tx

cannabidiol + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• methohexital
Epidiolex (cannabidiol (CBD))

+

methohexital

1 interaction

Monitor/Modify Tx

cannabidiol + methohexital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• mirtazapine
Epidiolex (cannabidiol (CBD))

+

mirtazapine

1 interaction

Monitor/Modify Tx

cannabidiol + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, mirtazapine may decr. seizure threshold)

• mitotane
Epidiolex (cannabidiol (CBD))

+

mitotane

1 interaction

Monitor/Modify Tx

cannabidiol + mitotane

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• morphine
Epidiolex (cannabidiol (CBD))

+

morphine

1 interaction

Monitor/Modify Tx

cannabidiol + morphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. oral morphine levels, risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (gut P-gp-mediated transport inhibited, additive effects; antagonistic effects, morphine may decr. seizure threshold)

• mycophenolate mofetil
Epidiolex (cannabidiol (CBD))

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

cannabidiol + mycophenolate mofetil

monitor CBC, consider monitoring mycophenolic acid levels: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, CNS depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

• mycophenolic acid
Epidiolex (cannabidiol (CBD))

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

cannabidiol + mycophenolic acid

monitor CBC: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, other adverse effects (UGT possibly inhibited)

• nalbuphine
Epidiolex (cannabidiol (CBD))

+

nalbuphine

1 interaction

Monitor/Modify Tx

cannabidiol + nalbuphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nalbuphine may decr. seizure threshold)

• nelarabine
Epidiolex (cannabidiol (CBD))

+

nelarabine

1 interaction

Monitor/Modify Tx

cannabidiol + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nelarabine may decr. seizure threshold)

• nintedanib
Epidiolex (cannabidiol (CBD))

+

nintedanib

1 interaction

Monitor/Modify Tx

cannabidiol + nintedanib

consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• olanzapine
Epidiolex (cannabidiol (CBD))

+

olanzapine

1 interaction

Monitor/Modify Tx

cannabidiol + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, incl. orthostasis; may alter seizure control (additive effects; antagonistic effects, olanzapine may decr. seizure threshold)

• oliceridine
Epidiolex (cannabidiol (CBD))

+

oliceridine

1 interaction

Monitor/Modify Tx

cannabidiol + oliceridine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, oliceridine may decr. seizure threshold)

• omeprazole
Epidiolex (cannabidiol (CBD))

+

omeprazole

1 interaction

Monitor/Modify Tx

cannabidiol + omeprazole

consider decr. omeprazole dose if dose >40 mg, especially if also combined w/ a CYP3A4 inhibitor: combo may incr. omeprazole levels, risk of adverse effects (hepatic metab. inhibited)

• opicapone
Epidiolex (cannabidiol (CBD))

+

opicapone

1 interaction

Monitor/Modify Tx

cannabidiol + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Epidiolex (cannabidiol (CBD))

+

opium

1 interaction

Monitor/Modify Tx

cannabidiol + opium

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, morphine in opium may decr. seizure threshold)

• oxazepam
Epidiolex (cannabidiol (CBD))

+

oxazepam

1 interaction

Monitor/Modify Tx

cannabidiol + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Epidiolex (cannabidiol (CBD))

+

oxybutynin

1 interaction

Monitor/Modify Tx

cannabidiol + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• oxycodone
Epidiolex (cannabidiol (CBD))

+

oxycodone

1 interaction

Monitor/Modify Tx

cannabidiol + oxycodone

monitor resp. rate; decr. oxycodone start dose by at least 50%, consider decr. cannabidiol dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxycodone may decr. seizure threshold)

• oxymorphone
Epidiolex (cannabidiol (CBD))

+

oxymorphone

1 interaction

Monitor/Modify Tx

cannabidiol + oxymorphone

monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. cannabidiol dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxymorphone may decr. seizure threshold)

• paclitaxel
Epidiolex (cannabidiol (CBD))

+

paclitaxel

1 interaction

Monitor/Modify Tx

cannabidiol + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. possibly inhibited)

• pentazocine
Epidiolex (cannabidiol (CBD))

+

pentazocine

1 interaction

Monitor/Modify Tx

cannabidiol + pentazocine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, pentazocine may decr. seizure threshold)

• pentobarbital
Epidiolex (cannabidiol (CBD))

+

pentobarbital

1 interaction

Monitor/Modify Tx

cannabidiol + pentobarbital

monitor resp. rate; consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• perphenazine
Epidiolex (cannabidiol (CBD))

+

perphenazine

1 interaction

Monitor/Modify Tx

cannabidiol + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, perphenazine may decr. seizure threshold)

• phenobarbital
Epidiolex (cannabidiol (CBD))

+

phenobarbital

1 interaction

Monitor/Modify Tx

cannabidiol + phenobarbital

monitor resp. rate; consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• phenytoin
Epidiolex (cannabidiol (CBD))

+

phenytoin

1 interaction

Monitor/Modify Tx

cannabidiol + phenytoin

monitor phenytoin levels; consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. phenytoin levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced; hepatic metab. inhibited, additive effects)

• pitavastatin
Epidiolex (cannabidiol (CBD))

+

pitavastatin

1 interaction

Monitor/Modify Tx

cannabidiol + pitavastatin

monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited)

• posaconazole
Epidiolex (cannabidiol (CBD))

+

posaconazole

1 interaction

Monitor/Modify Tx

cannabidiol + posaconazole

monitor ECG w/ oral posaconazole: combo may incr. posaconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• pravastatin
Epidiolex (cannabidiol (CBD))

+

pravastatin

1 interaction

Monitor/Modify Tx

cannabidiol + pravastatin

monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited)

• pregabalin
Epidiolex (cannabidiol (CBD))

+

pregabalin

1 interaction

Monitor/Modify Tx

cannabidiol + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• primidone
Epidiolex (cannabidiol (CBD))

+

primidone

1 interaction

Monitor/Modify Tx

cannabidiol + primidone

monitor resp. rate; consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• propofol
Epidiolex (cannabidiol (CBD))

+

propofol

1 interaction

Monitor/Modify Tx

cannabidiol + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. propofol levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may alter seizure control (UGT possibly inhibited; additive effects; antagonistic effects, propofol may decr. seizure threshold)

• quazepam
Epidiolex (cannabidiol (CBD))

+

quazepam

1 interaction

Monitor/Modify Tx

cannabidiol + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quinidine (antiarrhythmic)
Epidiolex (cannabidiol (CBD))

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

cannabidiol + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• quinidine (CYP2D6 inhibitor)
Epidiolex (cannabidiol (CBD))

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

cannabidiol + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• quinine
Epidiolex (cannabidiol (CBD))

+

quinine

1 interaction

Monitor/Modify Tx

cannabidiol + quinine

monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, quinine may decr. seizure threshold)

• ranolazine
Epidiolex (cannabidiol (CBD))

+

ranolazine

1 interaction

Monitor/Modify Tx

cannabidiol + ranolazine

monitor ECG; consider decr. ranolazine dose: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• red yeast rice
Epidiolex (cannabidiol (CBD))

+

red yeast rice

1 interaction

Monitor/Modify Tx

cannabidiol + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited, red yeast rice contains varying amounts of lovastatin)

• remifentanil
Epidiolex (cannabidiol (CBD))

+

remifentanil

1 interaction

Monitor/Modify Tx

cannabidiol + remifentanil

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, remifentanil may decr. seizure threshold)

• remimazolam
Epidiolex (cannabidiol (CBD))

+

remimazolam

1 interaction

Monitor/Modify Tx

cannabidiol + remimazolam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• repaglinide
Epidiolex (cannabidiol (CBD))

+

repaglinide

1 interaction

Monitor/Modify Tx

cannabidiol + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metab. possibly inhibited)

• rifabutin
Epidiolex (cannabidiol (CBD))

+

rifabutin

1 interaction

Monitor/Modify Tx

cannabidiol + rifabutin

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• rifampin
Epidiolex (cannabidiol (CBD))

+

rifampin

1 interaction

Monitor/Modify Tx

cannabidiol + rifampin

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy; may incr. oral rifampin levels, risk of adverse effects (hepatic metab. induced; gut P-gp-mediated transport inhibited)

• rimegepant
Epidiolex (cannabidiol (CBD))

+

rimegepant

1 interaction

Monitor/Modify Tx

cannabidiol + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• riociguat
Epidiolex (cannabidiol (CBD))

+

riociguat

1 interaction

Monitor/Modify Tx

cannabidiol + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (gut P-gp-mediated transport inhibited)

• sevoflurane
Epidiolex (cannabidiol (CBD))

+

sevoflurane

1 interaction

Monitor/Modify Tx

cannabidiol + sevoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sevoflurane may decr. seizure threshold)

• simvastatin
Epidiolex (cannabidiol (CBD))

+

simvastatin

1 interaction

Monitor/Modify Tx

cannabidiol + simvastatin

monitor CK, myopathy sx: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (gut P-gp-mediated transport inhibited)

• sirolimus
Epidiolex (cannabidiol (CBD))

+

sirolimus

1 interaction

Monitor/Modify Tx

cannabidiol + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (gut P-gp-mediated transport inhibited)

• St. John's wort
Epidiolex (cannabidiol (CBD))

+

St. John's wort

1 interaction

Monitor/Modify Tx

cannabidiol + St. John's wort

consider cannabidiol dose adjustment: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• sufentanil
Epidiolex (cannabidiol (CBD))

+

sufentanil

1 interaction

Monitor/Modify Tx

cannabidiol + sufentanil

monitor resp. rate, decr. sufentanil start dose, consider decr. cannabidiol dose, use lowest effective doses: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sufentanil may decr. seizure threshold)

• suvorexant
Epidiolex (cannabidiol (CBD))

+

suvorexant

1 interaction

Monitor/Modify Tx

cannabidiol + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tacrolimus
Epidiolex (cannabidiol (CBD))

+

tacrolimus

1 interaction

Monitor/Modify Tx

cannabidiol + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, tacrolimus may decr. seizure threshold)

• talazoparib
Epidiolex (cannabidiol (CBD))

+

talazoparib

1 interaction

Monitor/Modify Tx

cannabidiol + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• tapentadol
Epidiolex (cannabidiol (CBD))

+

tapentadol

1 interaction

Monitor/Modify Tx

cannabidiol + tapentadol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tapentadol may decr. seizure threshold)

• temazepam
Epidiolex (cannabidiol (CBD))

+

temazepam

1 interaction

Monitor/Modify Tx

cannabidiol + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• tenofovir alafenamide
Epidiolex (cannabidiol (CBD))

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

cannabidiol + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn w/ oral cannabidiol: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tenofovir disoproxil
Epidiolex (cannabidiol (CBD))

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

cannabidiol + tenofovir disoproxil

monitor renal fxn w/ oral cannabidiol: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• theophylline
Epidiolex (cannabidiol (CBD))

+

theophylline

1 interaction

Monitor/Modify Tx

cannabidiol + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities; may alter seizure control (hepatic metab. inhibited; antagonistic effects, theophylline may decr. seizure threshold)

• thioridazine
Epidiolex (cannabidiol (CBD))

+

thioridazine

1 interaction

Monitor/Modify Tx

cannabidiol + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thioridazine may decr. seizure threshold)

• thiothixene
Epidiolex (cannabidiol (CBD))

+

thiothixene

1 interaction

Monitor/Modify Tx

cannabidiol + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiothixene may decr. seizure threshold)

• tofacitinib
Epidiolex (cannabidiol (CBD))

+

tofacitinib

1 interaction

Monitor/Modify Tx

cannabidiol + tofacitinib

if also combined w/ CYP3A4 inhibitor, monitor CBC: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• torsemide
Epidiolex (cannabidiol (CBD))

+

torsemide

1 interaction

Monitor/Modify Tx

cannabidiol + torsemide

monitor renal fxn, BP: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects (hepatic metab. inhibited)

• tramadol
Epidiolex (cannabidiol (CBD))

+

tramadol

1 interaction

Monitor/Modify Tx

cannabidiol + tramadol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tramadol may decr. seizure threshold)

• triazolam
Epidiolex (cannabidiol (CBD))

+

triazolam

1 interaction

Monitor/Modify Tx

cannabidiol + triazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ubrogepant
Epidiolex (cannabidiol (CBD))

+

ubrogepant

1 interaction

Monitor/Modify Tx

cannabidiol + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• valproic acid
Epidiolex (cannabidiol (CBD))

+

valproic acid

1 interaction

Monitor/Modify Tx

cannabidiol + valproic acid

monitor ALT, AST, total bilirubin, ammonia levels: combo may incr. risk of CNS depression, psychomotor impairment, hepatocellular injury, hyperammonemia (additive effects)

• voriconazole
Epidiolex (cannabidiol (CBD))

+

voriconazole

1 interaction

Monitor/Modify Tx

cannabidiol + voriconazole

monitor ECG: combo may incr. voriconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• warfarin
Epidiolex (cannabidiol (CBD))

+

warfarin

1 interaction

Monitor/Modify Tx

cannabidiol + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• zaleplon
Epidiolex (cannabidiol (CBD))

+

zaleplon

1 interaction

Monitor/Modify Tx

cannabidiol + zaleplon

consider dose reduction of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Epidiolex (cannabidiol (CBD))

+

ziconotide

1 interaction

Monitor/Modify Tx

cannabidiol + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Epidiolex (cannabidiol (CBD))

+

zolpidem

1 interaction

Monitor/Modify Tx

cannabidiol + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

• 5-HTP
Epidiolex (cannabidiol (CBD))

+

5-HTP

1 interaction

Caution Advised

cannabidiol + 5-HTP

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• acyclovir
Epidiolex (cannabidiol (CBD))

+

acyclovir

1 interaction

Caution Advised

cannabidiol + acyclovir

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, acyclovir may decr. seizure threshold)

• aliskiren
Epidiolex (cannabidiol (CBD))

+

aliskiren

1 interaction

Caution Advised

cannabidiol + aliskiren

caution advised: combo may incr. aliskiren levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• allopurinol
Epidiolex (cannabidiol (CBD))

+

allopurinol

1 interaction

Caution Advised

cannabidiol + allopurinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• almotriptan
Epidiolex (cannabidiol (CBD))

+

almotriptan

1 interaction

Caution Advised

cannabidiol + almotriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alosetron
Epidiolex (cannabidiol (CBD))

+

alosetron

1 interaction

Caution Advised

cannabidiol + alosetron

caution advised: combo may incr. alosetron levels, risk of adverse effects (hepatic metab. inhibited)

• amantadine
Epidiolex (cannabidiol (CBD))

+

amantadine

1 interaction

Caution Advised

cannabidiol + amantadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amitriptyline
Epidiolex (cannabidiol (CBD))

+

amitriptyline

1 interaction

Caution Advised

cannabidiol + amitriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, amitriptyline may decr. seizure threshold)

• amoxapine
Epidiolex (cannabidiol (CBD))

+

amoxapine

1 interaction

Caution Advised

cannabidiol + amoxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, amoxapine may decr. seizure threshold)

• amoxicillin
Epidiolex (cannabidiol (CBD))

+

amoxicillin

1 interaction

Caution Advised

cannabidiol + amoxicillin

caution advised, especially w/ high amoxicillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, amoxicillin may decr. seizure threshold)

• amphetamine
Epidiolex (cannabidiol (CBD))

+

amphetamine

1 interaction

Caution Advised

cannabidiol + amphetamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, amphetamine may decr. seizure threshold)

• ampicillin
Epidiolex (cannabidiol (CBD))

+

ampicillin

1 interaction

Caution Advised

cannabidiol + ampicillin

caution advised, especially w/ high ampicillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, ampicillin may decr. seizure threshold)

• apomorphine
Epidiolex (cannabidiol (CBD))

+

apomorphine

1 interaction

Caution Advised

cannabidiol + apomorphine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Epidiolex (cannabidiol (CBD))

+

apraclonidine ophthalmic

1 interaction

Caution Advised

cannabidiol + apraclonidine ophthalmic

caution advised if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole bimonthly injection
Epidiolex (cannabidiol (CBD))

+

aripiprazole bimonthly injection

1 interaction

Caution Advised

cannabidiol + aripiprazole bimonthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• aripiprazole lauroxil
Epidiolex (cannabidiol (CBD))

+

aripiprazole lauroxil

1 interaction

Caution Advised

cannabidiol + aripiprazole lauroxil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• aripiprazole monthly injection
Epidiolex (cannabidiol (CBD))

+

aripiprazole monthly injection

1 interaction

Caution Advised

cannabidiol + aripiprazole monthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• aripiprazole oral
Epidiolex (cannabidiol (CBD))

+

aripiprazole oral

1 interaction

Caution Advised

cannabidiol + aripiprazole oral

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

• artesunate
Epidiolex (cannabidiol (CBD))

+

artesunate

1 interaction

Caution Advised

cannabidiol + artesunate

caution advised: combo may incr. dihydroartemisinin levels, risk of adverse effects (UGT possibly inhibited; artesunate converted to dihydroartemisinin by esterases)

• asenapine
Epidiolex (cannabidiol (CBD))

+

asenapine

1 interaction

Caution Advised

cannabidiol + asenapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, asenapine may decr. seizure threshold)

• axicabtagene ciloleucel
Epidiolex (cannabidiol (CBD))

+

axicabtagene ciloleucel

1 interaction

Caution Advised

cannabidiol + axicabtagene ciloleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, axicabtagene ciloleucel may decr. seizure threshold)

• baclofen
Epidiolex (cannabidiol (CBD))

+

baclofen

1 interaction

Caution Advised

cannabidiol + baclofen

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, baclofen may decr. seizure threshold)

• benzphetamine
Epidiolex (cannabidiol (CBD))

+

benzphetamine

1 interaction

Caution Advised

cannabidiol + benzphetamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, benzphetamine may decr. seizure threshold)

• betamethasone
Epidiolex (cannabidiol (CBD))

+

betamethasone

1 interaction

Caution Advised

cannabidiol + betamethasone

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, betamethasone may decr. seizure threshold)

• brexpiprazole
Epidiolex (cannabidiol (CBD))

+

brexpiprazole

1 interaction

Caution Advised

cannabidiol + brexpiprazole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, brexpiprazole may decr. seizure threshold)

• brexucabtagene autoleucel
Epidiolex (cannabidiol (CBD))

+

brexucabtagene autoleucel

1 interaction

Caution Advised

cannabidiol + brexucabtagene autoleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, brexucabtagene autoleucel may decr. seizure threshold)

• brimonidine ophthalmic
Epidiolex (cannabidiol (CBD))

+

brimonidine ophthalmic

1 interaction

Caution Advised

cannabidiol + brimonidine ophthalmic

caution advised if elevated IOP use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine topical
Epidiolex (cannabidiol (CBD))

+

brimonidine topical

1 interaction

Caution Advised

cannabidiol + brimonidine topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Epidiolex (cannabidiol (CBD))

+

brivaracetam

1 interaction

Caution Advised

cannabidiol + brivaracetam

caution advised: combo may incr. brivaracetam levels, risk of CNS depression, psychomotor impairment, other adverse effects (mechanism unknown, additive effects)

• bromocriptine
Epidiolex (cannabidiol (CBD))

+

bromocriptine

1 interaction

Caution Advised

cannabidiol + bromocriptine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brompheniramine
Epidiolex (cannabidiol (CBD))

+

brompheniramine

1 interaction

Caution Advised

cannabidiol + brompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• buspirone
Epidiolex (cannabidiol (CBD))

+

buspirone

1 interaction

Caution Advised

cannabidiol + buspirone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• busulfan
Epidiolex (cannabidiol (CBD))

+

busulfan

1 interaction

Caution Advised

cannabidiol + busulfan

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, busulfan may decr. seizure threshold)

• carbinoxamine
Epidiolex (cannabidiol (CBD))

+

carbinoxamine

1 interaction

Caution Advised

cannabidiol + carbinoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cariprazine
Epidiolex (cannabidiol (CBD))

+

cariprazine

1 interaction

Caution Advised

cannabidiol + cariprazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cariprazine may decr. seizure threshold)

• carisoprodol
Epidiolex (cannabidiol (CBD))

+

carisoprodol

1 interaction

Caution Advised

cannabidiol + carisoprodol

caution advised: combo may incr. carisoprodol levels, decr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. inhibited, decr. conversion to active metabolite; additive effects)

• cefazolin
Epidiolex (cannabidiol (CBD))

+

cefazolin

1 interaction

Caution Advised

cannabidiol + cefazolin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefazolin may decr. seizure threshold)

• cefepime
Epidiolex (cannabidiol (CBD))

+

cefepime

1 interaction

Caution Advised

cannabidiol + cefepime

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefepime may decr. seizure threshold)

• cefiderocol
Epidiolex (cannabidiol (CBD))

+

cefiderocol

1 interaction

Caution Advised

cannabidiol + cefiderocol

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefiderocol may decr. seizure threshold)

• ceftaroline
Epidiolex (cannabidiol (CBD))

+

ceftaroline

1 interaction

Caution Advised

cannabidiol + ceftaroline

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftaroline may decr. seizure threshold)

• ceftazidime
Epidiolex (cannabidiol (CBD))

+

ceftazidime

1 interaction

Caution Advised

cannabidiol + ceftazidime

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftazidime may decr. seizure threshold)

• ceftobiprole
Epidiolex (cannabidiol (CBD))

+

ceftobiprole

1 interaction

Caution Advised

cannabidiol + ceftobiprole

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftobiprole may decr. seizure threshold)

• cenobamate
Epidiolex (cannabidiol (CBD))

+

cenobamate

1 interaction

Caution Advised

cannabidiol + cenobamate

caution advised: combo may decr. cannabidiol levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• cetirizine
Epidiolex (cannabidiol (CBD))

+

cetirizine

1 interaction

Caution Advised

cannabidiol + cetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chamomile, German
Epidiolex (cannabidiol (CBD))

+

chamomile, German

1 interaction

Caution Advised

cannabidiol + chamomile, German

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Epidiolex (cannabidiol (CBD))

+

chlophedianol

1 interaction

Caution Advised

cannabidiol + chlophedianol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorambucil
Epidiolex (cannabidiol (CBD))

+

chlorambucil

1 interaction

Caution Advised

cannabidiol + chlorambucil

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, chlorambucil may decr. seizure threshold)

• chloroquine
Epidiolex (cannabidiol (CBD))

+

chloroquine

1 interaction

Caution Advised

cannabidiol + chloroquine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, chloroquine may decr. seizure threshold)

• chlorpheniramine
Epidiolex (cannabidiol (CBD))

+

chlorpheniramine

1 interaction

Caution Advised

cannabidiol + chlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorzoxazone
Epidiolex (cannabidiol (CBD))

+

chlorzoxazone

1 interaction

Caution Advised

cannabidiol + chlorzoxazone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ciltacabtagene autoleucel
Epidiolex (cannabidiol (CBD))

+

ciltacabtagene autoleucel

1 interaction

Caution Advised

cannabidiol + ciltacabtagene autoleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ciltacabtagene autoleucel may decr. seizure threshold)

• ciprofloxacin
Epidiolex (cannabidiol (CBD))

+

ciprofloxacin

1 interaction

Caution Advised

cannabidiol + ciprofloxacin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ciprofloxacin may decr. seizure threshold)

• cisatracurium
Epidiolex (cannabidiol (CBD))

+

cisatracurium

1 interaction

Caution Advised

cannabidiol + cisatracurium

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cisatracurium active metabolite may decr. seizure threshold)

• clemastine
Epidiolex (cannabidiol (CBD))

+

clemastine

1 interaction

Caution Advised

cannabidiol + clemastine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clomipramine
Epidiolex (cannabidiol (CBD))

+

clomipramine

1 interaction

Caution Advised

cannabidiol + clomipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, clomipramine may decr. seizure threshold)

• cocaine
Epidiolex (cannabidiol (CBD))

+

cocaine

1 interaction

Caution Advised

cannabidiol + cocaine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cocaine may decr. seizure threshold)

• cortisone
Epidiolex (cannabidiol (CBD))

+

cortisone

1 interaction

Caution Advised

cannabidiol + cortisone

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cortisone may decr. seizure threshold)

• cyclobenzaprine
Epidiolex (cannabidiol (CBD))

+

cyclobenzaprine

1 interaction

Caution Advised

cannabidiol + cyclobenzaprine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• cycloserine
Epidiolex (cannabidiol (CBD))

+

cycloserine

1 interaction

Caution Advised

cannabidiol + cycloserine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cycloserine may decr. seizure threshold)

• cyproheptadine
Epidiolex (cannabidiol (CBD))

+

cyproheptadine

1 interaction

Caution Advised

cannabidiol + cyproheptadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dabrafenib
Epidiolex (cannabidiol (CBD))

+

dabrafenib

1 interaction

Caution Advised

cannabidiol + dabrafenib

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• dantrolene
Epidiolex (cannabidiol (CBD))

+

dantrolene

1 interaction

Caution Advised

cannabidiol + dantrolene

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darbepoetin alfa
Epidiolex (cannabidiol (CBD))

+

darbepoetin alfa

1 interaction

Caution Advised

cannabidiol + darbepoetin alfa

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darbepoetin alfa may decr. seizure threshold)

• darifenacin
Epidiolex (cannabidiol (CBD))

+

darifenacin

1 interaction

Caution Advised

cannabidiol + darifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darolutamide
Epidiolex (cannabidiol (CBD))

+

darolutamide

1 interaction

Caution Advised

cannabidiol + darolutamide

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, darolutamide may decr. seizure threshold)

• deflazacort
Epidiolex (cannabidiol (CBD))

+

deflazacort

1 interaction

Caution Advised

cannabidiol + deflazacort

caution advised: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, deflazacort may decr. seizure threshold)

• delafloxacin
Epidiolex (cannabidiol (CBD))

+

delafloxacin

1 interaction

Caution Advised

cannabidiol + delafloxacin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, delafloxacin may decr. seizure threshold)

• desipramine
Epidiolex (cannabidiol (CBD))

+

desipramine

1 interaction

Caution Advised

cannabidiol + desipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, desipramine may decr. seizure threshold)

• desvenlafaxine
Epidiolex (cannabidiol (CBD))

+

desvenlafaxine

1 interaction

Caution Advised

cannabidiol + desvenlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, desvenlafaxine may decr. seizure threshold)

• deutetrabenazine
Epidiolex (cannabidiol (CBD))

+

deutetrabenazine

1 interaction

Caution Advised

cannabidiol + deutetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexamethasone
Epidiolex (cannabidiol (CBD))

+

dexamethasone

1 interaction

Caution Advised

cannabidiol + dexamethasone

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dexamethasone may decr. seizure threshold)

• dexbrompheniramine
Epidiolex (cannabidiol (CBD))

+

dexbrompheniramine

1 interaction

Caution Advised

cannabidiol + dexbrompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexchlorpheniramine
Epidiolex (cannabidiol (CBD))

+

dexchlorpheniramine

1 interaction

Caution Advised

cannabidiol + dexchlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexlansoprazole
Epidiolex (cannabidiol (CBD))

+

dexlansoprazole

1 interaction

Caution Advised

cannabidiol + dexlansoprazole

caution advised: combo may incr. dexlansoprazole levels, risk of adverse effects (hepatic metab. inhibited)

• dexmethylphenidate
Epidiolex (cannabidiol (CBD))

+

dexmethylphenidate

1 interaction

Caution Advised

cannabidiol + dexmethylphenidate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, (ser)dexmethylphenidate may decr. seizure threshold)

• dextroamphetamine
Epidiolex (cannabidiol (CBD))

+

dextroamphetamine

1 interaction

Caution Advised

cannabidiol + dextroamphetamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dextroamphetamine may decr. seizure threshold)

• dichlorphenamide
Epidiolex (cannabidiol (CBD))

+

dichlorphenamide

1 interaction

Caution Advised

cannabidiol + dichlorphenamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dicloxacillin
Epidiolex (cannabidiol (CBD))

+

dicloxacillin

1 interaction

Caution Advised

cannabidiol + dicloxacillin

caution advised: combo may decr. cannabidiol levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, dicloxacillin may decr. seizure threshold)

• diethylpropion
Epidiolex (cannabidiol (CBD))

+

diethylpropion

1 interaction

Caution Advised

cannabidiol + diethylpropion

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, diethylpropion may decr. seizure threshold)

• difelikefalin
Epidiolex (cannabidiol (CBD))

+

difelikefalin

1 interaction

Caution Advised

cannabidiol + difelikefalin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Epidiolex (cannabidiol (CBD))

+

difenoxin

1 interaction

Caution Advised

cannabidiol + difenoxin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diflunisal
Epidiolex (cannabidiol (CBD))

+

diflunisal

1 interaction

Caution Advised

cannabidiol + diflunisal

caution advised: combo may incr. diflunisal levels, risk of adverse effects (UGT possibly inhibited)

• dimenhydrinate
Epidiolex (cannabidiol (CBD))

+

dimenhydrinate

1 interaction

Caution Advised

cannabidiol + dimenhydrinate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenhydramine
Epidiolex (cannabidiol (CBD))

+

diphenhydramine

1 interaction

Caution Advised

cannabidiol + diphenhydramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenoxylate
Epidiolex (cannabidiol (CBD))

+

diphenoxylate

1 interaction

Caution Advised

cannabidiol + diphenoxylate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• domperidone
Epidiolex (cannabidiol (CBD))

+

domperidone

1 interaction

Caution Advised

cannabidiol + domperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• donepezil
Epidiolex (cannabidiol (CBD))

+

donepezil

1 interaction

Caution Advised

cannabidiol + donepezil

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, donepezil may decr. seizure threshold)

• doxepin
Epidiolex (cannabidiol (CBD))

+

doxepin

1 interaction

Caution Advised

cannabidiol + doxepin

caution advised: combo may incr. doxepin levels, risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited, additive effects; antagonistic effects, doxepin may decr. seizure threshold)

• doxepin topical
Epidiolex (cannabidiol (CBD))

+

doxepin topical

1 interaction

Caution Advised

cannabidiol + doxepin topical

caution advised: combo may incr. doxepin levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• dronabinol
Epidiolex (cannabidiol (CBD))

+

dronabinol

1 interaction

Caution Advised

cannabidiol + dronabinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, dronabinol may decr. seizure threshold)

• duloxetine
Epidiolex (cannabidiol (CBD))

+

duloxetine

1 interaction

Caution Advised

cannabidiol + duloxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, duloxetine may decr. seizure threshold)

• efavirenz
Epidiolex (cannabidiol (CBD))

+

efavirenz

1 interaction

Caution Advised

cannabidiol + efavirenz

caution advised: combo may decr. levels, efficacy of both drugs; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• eletriptan
Epidiolex (cannabidiol (CBD))

+

eletriptan

1 interaction

Caution Advised

cannabidiol + eletriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• elivaldogene autotemcel
Epidiolex (cannabidiol (CBD))

+

elivaldogene autotemcel

1 interaction

Caution Advised

cannabidiol + elivaldogene autotemcel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, elivaldogene autotemcel may decr. seizure threshold)

• entacapone
Epidiolex (cannabidiol (CBD))

+

entacapone

1 interaction

Caution Advised

cannabidiol + entacapone

caution advised: combo may incr. entacapone levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

• entrectinib
Epidiolex (cannabidiol (CBD))

+

entrectinib

1 interaction

Caution Advised

cannabidiol + entrectinib

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ephedra
Epidiolex (cannabidiol (CBD))

+

ephedra

1 interaction

Caution Advised

cannabidiol + ephedra

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ephedra may decr. seizure threshold)

• epoetin alfa
Epidiolex (cannabidiol (CBD))

+

epoetin alfa

1 interaction

Caution Advised

cannabidiol + epoetin alfa

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, epoetin alfa may decr. seizure threshold)

• ertapenem
Epidiolex (cannabidiol (CBD))

+

ertapenem

1 interaction

Caution Advised

cannabidiol + ertapenem

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ertapenem may decr. seizure threshold)

• escitalopram
Epidiolex (cannabidiol (CBD))

+

escitalopram

1 interaction

Caution Advised

cannabidiol + escitalopram

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, escitalopram may decr. seizure threshold)

• eslicarbazepine acetate
Epidiolex (cannabidiol (CBD))

+

eslicarbazepine acetate

1 interaction

Caution Advised

cannabidiol + eslicarbazepine acetate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethosuximide
Epidiolex (cannabidiol (CBD))

+

ethosuximide

1 interaction

Caution Advised

cannabidiol + ethosuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• etravirine
Epidiolex (cannabidiol (CBD))

+

etravirine

1 interaction

Caution Advised

cannabidiol + etravirine

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• felbamate
Epidiolex (cannabidiol (CBD))

+

felbamate

1 interaction

Caution Advised

cannabidiol + felbamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fenfluramine
Epidiolex (cannabidiol (CBD))

+

fenfluramine

1 interaction

Caution Advised

cannabidiol + fenfluramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fenofibrate
Epidiolex (cannabidiol (CBD))

+

fenofibrate

1 interaction

Caution Advised

cannabidiol + fenofibrate

caution advised: combo may incr. fenofibric acid levels, risk of adverse effects (UGT possibly inhibited)

• fenofibric acid
Epidiolex (cannabidiol (CBD))

+

fenofibric acid

1 interaction

Caution Advised

cannabidiol + fenofibric acid

caution advised: combo may incr. fenofibric acid levels, risk of adverse effects (UGT possibly inhibited)

• fesoterodine
Epidiolex (cannabidiol (CBD))

+

fesoterodine

1 interaction

Caution Advised

cannabidiol + fesoterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fexinidazole
Epidiolex (cannabidiol (CBD))

+

fexinidazole

1 interaction

Caution Advised

cannabidiol + fexinidazole

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• fluoxetine
Epidiolex (cannabidiol (CBD))

+

fluoxetine

1 interaction

Caution Advised

cannabidiol + fluoxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fluoxetine may decr. seizure threshold)

• fluvoxamine
Epidiolex (cannabidiol (CBD))

+

fluvoxamine

1 interaction

Caution Advised

cannabidiol + fluvoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fluvoxamine may decr. seizure threshold)

• foscarnet
Epidiolex (cannabidiol (CBD))

+

foscarnet

1 interaction

Caution Advised

cannabidiol + foscarnet

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, foscarnet may decr. seizure threshold)

• foslevodopa
Epidiolex (cannabidiol (CBD))

+

foslevodopa

1 interaction

Caution Advised

cannabidiol + foslevodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• frovatriptan
Epidiolex (cannabidiol (CBD))

+

frovatriptan

1 interaction

Caution Advised

cannabidiol + frovatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• galantamine
Epidiolex (cannabidiol (CBD))

+

galantamine

1 interaction

Caution Advised

cannabidiol + galantamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, galantamine may decr. seizure threshold)

• ganaxolone
Epidiolex (cannabidiol (CBD))

+

ganaxolone

1 interaction

Caution Advised

cannabidiol + ganaxolone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ganciclovir
Epidiolex (cannabidiol (CBD))

+

ganciclovir

1 interaction

Caution Advised

cannabidiol + ganciclovir

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ganciclovir may decr. seizure threshold)

• gemfibrozil
Epidiolex (cannabidiol (CBD))

+

gemfibrozil

1 interaction

Caution Advised

cannabidiol + gemfibrozil

caution advised: combo may incr. gemfibrozil levels, risk of adverse effects (UGT possibly inhibited)

• glecaprevir
Epidiolex (cannabidiol (CBD))

+

glecaprevir

1 interaction

Caution Advised

cannabidiol + glecaprevir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• glofitamab
Epidiolex (cannabidiol (CBD))

+

glofitamab

1 interaction

Caution Advised

cannabidiol + glofitamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Epidiolex (cannabidiol (CBD))

+

glycopyrrolate

1 interaction

Caution Advised

cannabidiol + glycopyrrolate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• goserelin
Epidiolex (cannabidiol (CBD))

+

goserelin

1 interaction

Caution Advised

cannabidiol + goserelin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, goserelin may decr. seizure threshold)

• guanfacine
Epidiolex (cannabidiol (CBD))

+

guanfacine

1 interaction

Caution Advised

cannabidiol + guanfacine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• haloperidol
Epidiolex (cannabidiol (CBD))

+

haloperidol

1 interaction

Caution Advised

cannabidiol + haloperidol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, haloperidol may decr. seizure threshold)

• histrelin
Epidiolex (cannabidiol (CBD))

+

histrelin

1 interaction

Caution Advised

cannabidiol + histrelin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, histrelin may decr. seizure threshold)

• hydroxychloroquine
Epidiolex (cannabidiol (CBD))

+

hydroxychloroquine

1 interaction

Caution Advised

cannabidiol + hydroxychloroquine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, hydroxychloroquine may decr. seizure threshold)

• hyoscyamine
Epidiolex (cannabidiol (CBD))

+

hyoscyamine

1 interaction

Caution Advised

cannabidiol + hyoscyamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• idecabtagene vicleucel
Epidiolex (cannabidiol (CBD))

+

idecabtagene vicleucel

1 interaction

Caution Advised

cannabidiol + idecabtagene vicleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, idecabtagene vicleucel may decr. seizure threshold)

• iloperidone
Epidiolex (cannabidiol (CBD))

+

iloperidone

1 interaction

Caution Advised

cannabidiol + iloperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, iloperidone may decr. seizure threshold)

• imipenem
Epidiolex (cannabidiol (CBD))

+

imipenem

1 interaction

Caution Advised

cannabidiol + imipenem

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, imipenem may decr. seizure threshold)

• imipramine
Epidiolex (cannabidiol (CBD))

+

imipramine

1 interaction

Caution Advised

cannabidiol + imipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, imipramine may decr. seizure threshold)

• indomethacin
Epidiolex (cannabidiol (CBD))

+

indomethacin

1 interaction

Caution Advised

cannabidiol + indomethacin

caution advised: combo may incr. indomethacin levels, risk of adverse effects (UGT possibly inhibited)

• interferon beta 1a
Epidiolex (cannabidiol (CBD))

+

interferon beta 1a

1 interaction

Caution Advised

cannabidiol + interferon beta 1a

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, interferon beta 1a may decr. seizure threshold)

• interferon beta 1b
Epidiolex (cannabidiol (CBD))

+

interferon beta 1b

1 interaction

Caution Advised

cannabidiol + interferon beta 1b

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, interferon beta 1b may decr. seizure threshold)

• iohexol
Epidiolex (cannabidiol (CBD))

+

iohexol

1 interaction

Caution Advised

cannabidiol + iohexol

caution advised if intrathecal iohexol use: combo may alter seizure control (antagonistic effects, intrathecal iohexol may decr. seizure threshold)

• iopamidol
Epidiolex (cannabidiol (CBD))

+

iopamidol

1 interaction

Caution Advised

cannabidiol + iopamidol

caution advised if intrathecal iopamidol use: combo may alter seizure control (antagonistic effects, intrathecal iopamidol may decr. seizure threshold)

• isoniazid
Epidiolex (cannabidiol (CBD))

+

isoniazid

1 interaction

Caution Advised

cannabidiol + isoniazid

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, isoniazid may decr. seizure threshold)

• ketorolac
Epidiolex (cannabidiol (CBD))

+

ketorolac

1 interaction

Caution Advised

cannabidiol + ketorolac

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ketorolac may decr. seizure threshold)

• lacosamide
Epidiolex (cannabidiol (CBD))

+

lacosamide

1 interaction

Caution Advised

cannabidiol + lacosamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lansoprazole
Epidiolex (cannabidiol (CBD))

+

lansoprazole

1 interaction

Caution Advised

cannabidiol + lansoprazole

caution advised: combo may incr. lansoprazole levels, risk of adverse effects (hepatic metab. inhibited)

• larotrectinib
Epidiolex (cannabidiol (CBD))

+

larotrectinib

1 interaction

Caution Advised

cannabidiol + larotrectinib

caution advised: combo may incr. larotrectinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• lasmiditan
Epidiolex (cannabidiol (CBD))

+

lasmiditan

1 interaction

Caution Advised

cannabidiol + lasmiditan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• leuprolide
Epidiolex (cannabidiol (CBD))

+

leuprolide

1 interaction

Caution Advised

cannabidiol + leuprolide

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• levetiracetam
Epidiolex (cannabidiol (CBD))

+

levetiracetam

1 interaction

Caution Advised

cannabidiol + levetiracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levocarnitine
Epidiolex (cannabidiol (CBD))

+

levocarnitine

1 interaction

Caution Advised

cannabidiol + levocarnitine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, levocarnitine may decr. seizure threshold)

• levocetirizine
Epidiolex (cannabidiol (CBD))

+

levocetirizine

1 interaction

Caution Advised

cannabidiol + levocetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Epidiolex (cannabidiol (CBD))

+

levodopa

1 interaction

Caution Advised

cannabidiol + levodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levofloxacin
Epidiolex (cannabidiol (CBD))

+

levofloxacin

1 interaction

Caution Advised

cannabidiol + levofloxacin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, levofloxacin may decr. seizure threshold)

• levomilnacipran
Epidiolex (cannabidiol (CBD))

+

levomilnacipran

1 interaction

Caution Advised

cannabidiol + levomilnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, levomilnacipran may decr. seizure threshold)

• lidocaine
Epidiolex (cannabidiol (CBD))

+

lidocaine

1 interaction

Caution Advised

cannabidiol + lidocaine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lidocaine may decr. seizure threshold)

• lidocaine topical
Epidiolex (cannabidiol (CBD))

+

lidocaine topical

1 interaction

Caution Advised

cannabidiol + lidocaine topical

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lidocaine may decr. seizure threshold)

• linezolid
Epidiolex (cannabidiol (CBD))

+

linezolid

1 interaction

Caution Advised

cannabidiol + linezolid

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, linezolid may decr. seizure threshold)

• linvoseltamab
Epidiolex (cannabidiol (CBD))

+

linvoseltamab

1 interaction

Caution Advised

cannabidiol + linvoseltamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lisdexamfetamine
Epidiolex (cannabidiol (CBD))

+

lisdexamfetamine

1 interaction

Caution Advised

cannabidiol + lisdexamfetamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dextroamphetamine may decr. seizure threshold)

• lisocabtagene maraleucel
Epidiolex (cannabidiol (CBD))

+

lisocabtagene maraleucel

1 interaction

Caution Advised

cannabidiol + lisocabtagene maraleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lisocabtagene maraleucel may decr. seizure threshold)

• lithium
Epidiolex (cannabidiol (CBD))

+

lithium

1 interaction

Caution Advised

cannabidiol + lithium

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lithium may decr. seizure threshold)

• lofexidine
Epidiolex (cannabidiol (CBD))

+

lofexidine

1 interaction

Caution Advised

cannabidiol + lofexidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lopinavir/ritonavir
Epidiolex (cannabidiol (CBD))

+

lopinavir/ ritonavir

1 interaction

Caution Advised

cannabidiol + lopinavir/ ritonavir

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• lorlatinib
Epidiolex (cannabidiol (CBD))

+

lorlatinib

1 interaction

Caution Advised

cannabidiol + lorlatinib

caution advised: combo may decr. cannabidiol levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, lorlatinib may decr. seizure threshold)

• loxapine
Epidiolex (cannabidiol (CBD))

+

loxapine

1 interaction

Caution Advised

cannabidiol + loxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, loxapine may decr. seizure threshold)

• lumateperone
Epidiolex (cannabidiol (CBD))

+

lumateperone

1 interaction

Caution Advised

cannabidiol + lumateperone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• lurasidone
Epidiolex (cannabidiol (CBD))

+

lurasidone

1 interaction

Caution Advised

cannabidiol + lurasidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lurasidone may decr. seizure threshold)

• magnesium citrate
Epidiolex (cannabidiol (CBD))

+

magnesium citrate

1 interaction

Caution Advised

cannabidiol + magnesium citrate

caution advised, especially if magnesium citrate bowel prep use: combo may alter seizure control (antagonistic effects, magnesium citrate may decr. seizure threshold)

• maraviroc
Epidiolex (cannabidiol (CBD))

+

maraviroc

1 interaction

Caution Advised

cannabidiol + maraviroc

caution advised: combo may incr. maraviroc levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• meclizine
Epidiolex (cannabidiol (CBD))

+

meclizine

1 interaction

Caution Advised

cannabidiol + meclizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mefloquine
Epidiolex (cannabidiol (CBD))

+

mefloquine

1 interaction

Caution Advised

cannabidiol + mefloquine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, mefloquine may decr. seizure threshold)

• melatonin
Epidiolex (cannabidiol (CBD))

+

melatonin

1 interaction

Caution Advised

cannabidiol + melatonin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, melatonin may decr. seizure threshold)

• meprobamate
Epidiolex (cannabidiol (CBD))

+

meprobamate

1 interaction

Caution Advised

cannabidiol + meprobamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meropenem
Epidiolex (cannabidiol (CBD))

+

meropenem

1 interaction

Caution Advised

cannabidiol + meropenem

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, meropenem may decr. seizure threshold)

• methamphetamine
Epidiolex (cannabidiol (CBD))

+

methamphetamine

1 interaction

Caution Advised

cannabidiol + methamphetamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methamphetamine may decr. seizure threshold)

• methocarbamol
Epidiolex (cannabidiol (CBD))

+

methocarbamol

1 interaction

Caution Advised

cannabidiol + methocarbamol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, methocarbamol may decr. seizure threshold)

• methotrexate
Epidiolex (cannabidiol (CBD))

+

methotrexate

1 interaction

Caution Advised

cannabidiol + methotrexate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methotrexate may decr. seizure threshold)

• methoxy polyethylene glycol-epoetin beta
Epidiolex (cannabidiol (CBD))

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Caution Advised

cannabidiol + methoxy polyethylene glycol-epoetin beta

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methoxy polyethylene glycol-epoetin beta may decr. seizure threshold)

• methsuximide
Epidiolex (cannabidiol (CBD))

+

methsuximide

1 interaction

Caution Advised

cannabidiol + methsuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methyldopa
Epidiolex (cannabidiol (CBD))

+

methyldopa

1 interaction

Caution Advised

cannabidiol + methyldopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methylphenidate
Epidiolex (cannabidiol (CBD))

+

methylphenidate

1 interaction

Caution Advised

cannabidiol + methylphenidate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methylphenidate may decr. seizure threshold)

• metronidazole
Epidiolex (cannabidiol (CBD))

+

metronidazole

1 interaction

Caution Advised

cannabidiol + metronidazole

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, metronidazole may decr. seizure threshold)

• metyrapone
Epidiolex (cannabidiol (CBD))

+

metyrapone

1 interaction

Caution Advised

cannabidiol + metyrapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Epidiolex (cannabidiol (CBD))

+

metyrosine

1 interaction

Caution Advised

cannabidiol + metyrosine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mexiletine
Epidiolex (cannabidiol (CBD))

+

mexiletine

1 interaction

Caution Advised

cannabidiol + mexiletine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, mexiletine may decr. seizure threshold)

• milnacipran
Epidiolex (cannabidiol (CBD))

+

milnacipran

1 interaction

Caution Advised

cannabidiol + milnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milnacipran may decr. seizure threshold)

• mitapivat
Epidiolex (cannabidiol (CBD))

+

mitapivat

1 interaction

Caution Advised

cannabidiol + mitapivat

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• modafinil
Epidiolex (cannabidiol (CBD))

+

modafinil

1 interaction

Caution Advised

cannabidiol + modafinil

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• molindone
Epidiolex (cannabidiol (CBD))

+

molindone

1 interaction

Caution Advised

cannabidiol + molindone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, molindone may decr. seizure threshold)

• mosunetuzumab
Epidiolex (cannabidiol (CBD))

+

mosunetuzumab

1 interaction

Caution Advised

cannabidiol + mosunetuzumab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• moxifloxacin
Epidiolex (cannabidiol (CBD))

+

moxifloxacin

1 interaction

Caution Advised

cannabidiol + moxifloxacin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, moxifloxacin may decr. seizure threshold)

• nafarelin
Epidiolex (cannabidiol (CBD))

+

nafarelin

1 interaction

Caution Advised

cannabidiol + nafarelin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, nafarelin may decr. seizure threshold)

• nafcillin
Epidiolex (cannabidiol (CBD))

+

nafcillin

1 interaction

Caution Advised

cannabidiol + nafcillin

caution advised, especially w/ high nafcillin doses or concomitant renal impairment: combo may decr. cannabidiol levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, nafcillin may decr. seizure threshold)

• naldemedine
Epidiolex (cannabidiol (CBD))

+

naldemedine

1 interaction

Caution Advised

cannabidiol + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• naltrexone
Epidiolex (cannabidiol (CBD))

+

naltrexone

1 interaction

Caution Advised

cannabidiol + naltrexone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naratriptan
Epidiolex (cannabidiol (CBD))

+

naratriptan

1 interaction

Caution Advised

cannabidiol + naratriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nefazodone
Epidiolex (cannabidiol (CBD))

+

nefazodone

1 interaction

Caution Advised

cannabidiol + nefazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nefazodone may decr. seizure threshold)

• nevirapine
Epidiolex (cannabidiol (CBD))

+

nevirapine

1 interaction

Caution Advised

cannabidiol + nevirapine

caution advised: combo may decr. nevirapine levels, efficacy (hepatic metab. possibly induced)

• nortriptyline
Epidiolex (cannabidiol (CBD))

+

nortriptyline

1 interaction

Caution Advised

cannabidiol + nortriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nortriptyline may decr. seizure threshold)

• obecabtagene autoleucel
Epidiolex (cannabidiol (CBD))

+

obecabtagene autoleucel

1 interaction

Caution Advised

cannabidiol + obecabtagene autoleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, obecabtagene autoleucel may decr. seizure threshold)

• ofloxacin
Epidiolex (cannabidiol (CBD))

+

ofloxacin

1 interaction

Caution Advised

cannabidiol + ofloxacin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ofloxacin may decr. seizure threshold)

• orphenadrine
Epidiolex (cannabidiol (CBD))

+

orphenadrine

1 interaction

Caution Advised

cannabidiol + orphenadrine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• oxacillin
Epidiolex (cannabidiol (CBD))

+

oxacillin

1 interaction

Caution Advised

cannabidiol + oxacillin

caution advised, especially w/ high oxacillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, oxacillin may decr. seizure threshold)

• oxcarbazepine
Epidiolex (cannabidiol (CBD))

+

oxcarbazepine

1 interaction

Caution Advised

cannabidiol + oxcarbazepine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pacritinib
Epidiolex (cannabidiol (CBD))

+

pacritinib

1 interaction

Caution Advised

cannabidiol + pacritinib

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• paliperidone
Epidiolex (cannabidiol (CBD))

+

paliperidone

1 interaction

Caution Advised

cannabidiol + paliperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, paliperidone may decr. seizure threshold)

• paroxetine
Epidiolex (cannabidiol (CBD))

+

paroxetine

1 interaction

Caution Advised

cannabidiol + paroxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, paroxetine may decr. seizure threshold)

• passion flower
Epidiolex (cannabidiol (CBD))

+

passion flower

1 interaction

Caution Advised

cannabidiol + passion flower

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• peginterferon beta 1a
Epidiolex (cannabidiol (CBD))

+

peginterferon beta 1a

1 interaction

Caution Advised

cannabidiol + peginterferon beta 1a

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, peginterferon beta 1a may decr. seizure threshold)

• penicillin G
Epidiolex (cannabidiol (CBD))

+

penicillin G

1 interaction

Caution Advised

cannabidiol + penicillin G

caution advised, especially w/ high penicillin G doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, penicillin G may decr. seizure threshold)

• penicillin V
Epidiolex (cannabidiol (CBD))

+

penicillin V

1 interaction

Caution Advised

cannabidiol + penicillin V

caution advised, especially w/ high penicillin V doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, penicillin V may decr. seizure threshold)

• perampanel
Epidiolex (cannabidiol (CBD))

+

perampanel

1 interaction

Caution Advised

cannabidiol + perampanel

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pexidartinib
Epidiolex (cannabidiol (CBD))

+

pexidartinib

1 interaction

Caution Advised

cannabidiol + pexidartinib

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• phendimetrazine
Epidiolex (cannabidiol (CBD))

+

phendimetrazine

1 interaction

Caution Advised

cannabidiol + phendimetrazine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, phendimetrazine may decr. seizure threshold)

• pheniramine
Epidiolex (cannabidiol (CBD))

+

pheniramine

1 interaction

Caution Advised

cannabidiol + pheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• phentermine
Epidiolex (cannabidiol (CBD))

+

phentermine

1 interaction

Caution Advised

cannabidiol + phentermine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, phentermine may decr. seizure threshold)

• pibrentasvir
Epidiolex (cannabidiol (CBD))

+

pibrentasvir

1 interaction

Caution Advised

cannabidiol + pibrentasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• pimozide
Epidiolex (cannabidiol (CBD))

+

pimozide

1 interaction

Caution Advised

cannabidiol + pimozide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, pimozide may decr. seizure threshold)

• piperacillin
Epidiolex (cannabidiol (CBD))

+

piperacillin

1 interaction

Caution Advised

cannabidiol + piperacillin

caution advised, especially w/ high piperacillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, piperacillin may decr. seizure threshold)

• polyethylene glycol
Epidiolex (cannabidiol (CBD))

+

polyethylene glycol

1 interaction

Caution Advised

cannabidiol + polyethylene glycol

caution advised if polyethylene glycol bowel prep use: combo may alter seizure control (antagonistic effects, polyethylene glycol may decr. seizure threshold)

• polyethylene glycol/electrolytes
Epidiolex (cannabidiol (CBD))

+

polyethylene glycol/ electrolytes

1 interaction

Caution Advised

cannabidiol + polyethylene glycol/ electrolytes

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, polyethylene glycol/electrolytes may decr. seizure threshold)

• pramipexole
Epidiolex (cannabidiol (CBD))

+

pramipexole

1 interaction

Caution Advised

cannabidiol + pramipexole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• procarbazine
Epidiolex (cannabidiol (CBD))

+

procarbazine

1 interaction

Caution Advised

cannabidiol + procarbazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, procarbazine may decr. seizure threshold)

• prochlorperazine
Epidiolex (cannabidiol (CBD))

+

prochlorperazine

1 interaction

Caution Advised

cannabidiol + prochlorperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, prochlorperazine may decr. seizure threshold)

• proguanil
Epidiolex (cannabidiol (CBD))

+

proguanil

1 interaction

Caution Advised

cannabidiol + proguanil

caution advised: combo may incr. proguanil levels, risk of adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metab. inhibited, decr. conversion to active metabolite)

• protriptyline
Epidiolex (cannabidiol (CBD))

+

protriptyline

1 interaction

Caution Advised

cannabidiol + protriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, protriptyline may decr. seizure threshold)

• pyridostigmine
Epidiolex (cannabidiol (CBD))

+

pyridostigmine

1 interaction

Caution Advised

cannabidiol + pyridostigmine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, pyridostigmine may decr. seizure threshold)

• pyrilamine
Epidiolex (cannabidiol (CBD))

+

pyrilamine

1 interaction

Caution Advised

cannabidiol + pyrilamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pyrimethamine
Epidiolex (cannabidiol (CBD))

+

pyrimethamine

1 interaction

Caution Advised

cannabidiol + pyrimethamine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, pyrimethamine may decr. seizure threshold)

• quetiapine
Epidiolex (cannabidiol (CBD))

+

quetiapine

1 interaction

Caution Advised

cannabidiol + quetiapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, quetiapine may decr. seizure threshold)

• ramelteon
Epidiolex (cannabidiol (CBD))

+

ramelteon

1 interaction

Caution Advised

cannabidiol + ramelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rasagiline
Epidiolex (cannabidiol (CBD))

+

rasagiline

1 interaction

Caution Advised

cannabidiol + rasagiline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• regadenoson
Epidiolex (cannabidiol (CBD))

+

regadenoson

1 interaction

Caution Advised

cannabidiol + regadenoson

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, regadenoson may decr. seizure threshold)

• rifapentine
Epidiolex (cannabidiol (CBD))

+

rifapentine

1 interaction

Caution Advised

cannabidiol + rifapentine

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• rifaximin
Epidiolex (cannabidiol (CBD))

+

rifaximin

1 interaction

Caution Advised

cannabidiol + rifaximin

caution advised: combo may incr. rifaximin levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• risperidone
Epidiolex (cannabidiol (CBD))

+

risperidone

1 interaction

Caution Advised

cannabidiol + risperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, risperidone may decr. seizure threshold)

• rivastigmine
Epidiolex (cannabidiol (CBD))

+

rivastigmine

1 interaction

Caution Advised

cannabidiol + rivastigmine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, rivastigmine may decr. seizure threshold)

• rizatriptan
Epidiolex (cannabidiol (CBD))

+

rizatriptan

1 interaction

Caution Advised

cannabidiol + rizatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• roflumilast
Epidiolex (cannabidiol (CBD))

+

roflumilast

1 interaction

Caution Advised

cannabidiol + roflumilast

if also combined w/ CYP3A4 inhibitor, caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• roflumilast topical
Epidiolex (cannabidiol (CBD))

+

roflumilast topical

1 interaction

Caution Advised

cannabidiol + roflumilast topical

if also combined w/ CYP3A4 inhibitor, caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• ropinirole
Epidiolex (cannabidiol (CBD))

+

ropinirole

1 interaction

Caution Advised

cannabidiol + ropinirole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Epidiolex (cannabidiol (CBD))

+

rotigotine transdermal

1 interaction

Caution Advised

cannabidiol + rotigotine transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rufinamide
Epidiolex (cannabidiol (CBD))

+

rufinamide

1 interaction

Caution Advised

cannabidiol + rufinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• safinamide
Epidiolex (cannabidiol (CBD))

+

safinamide

1 interaction

Caution Advised

cannabidiol + safinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Epidiolex (cannabidiol (CBD))

+

scopolamine

1 interaction

Caution Advised

cannabidiol + scopolamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, scopolamine may decr. seizure threshold)

• selegiline
Epidiolex (cannabidiol (CBD))

+

selegiline

1 interaction

Caution Advised

cannabidiol + selegiline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Epidiolex (cannabidiol (CBD))

+

selegiline transdermal

1 interaction

Caution Advised

cannabidiol + selegiline transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, selegiline transdermal may decr. seizure threshold)

• selinexor
Epidiolex (cannabidiol (CBD))

+

selinexor

1 interaction

Caution Advised

cannabidiol + selinexor

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sertraline
Epidiolex (cannabidiol (CBD))

+

sertraline

1 interaction

Caution Advised

cannabidiol + sertraline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sertraline may decr. seizure threshold)

• sodium picosulfate
Epidiolex (cannabidiol (CBD))

+

sodium picosulfate

1 interaction

Caution Advised

cannabidiol + sodium picosulfate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, sodium picosulfate may decr. seizure threshold)

• solifenacin
Epidiolex (cannabidiol (CBD))

+

solifenacin

1 interaction

Caution Advised

cannabidiol + solifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sotorasib
Epidiolex (cannabidiol (CBD))

+

sotorasib

1 interaction

Caution Advised

cannabidiol + sotorasib

caution advised: combo may decr. cannabidiol levels, efficacy (hepatic metab. induced)

• stiripentol
Epidiolex (cannabidiol (CBD))

+

stiripentol

1 interaction

Caution Advised

cannabidiol + stiripentol

caution advised: combo may incr. stiripentol levels, risk of CNS depression, psychomotor impairment, other adverse effects (mechanism unknown; additive effects)

• sulfate bowel prep
Epidiolex (cannabidiol (CBD))

+

sulfate bowel prep

1 interaction

Caution Advised

cannabidiol + sulfate bowel prep

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, sulfate bowel prep may decr. seizure threshold)

• sumatriptan
Epidiolex (cannabidiol (CBD))

+

sumatriptan

1 interaction

Caution Advised

cannabidiol + sumatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sumatriptan may decr. seizure threshold)

• tasimelteon
Epidiolex (cannabidiol (CBD))

+

tasimelteon

1 interaction

Caution Advised

cannabidiol + tasimelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• teclistamab
Epidiolex (cannabidiol (CBD))

+

teclistamab

1 interaction

Caution Advised

cannabidiol + teclistamab

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, teclistamab may decr. seizure threshold)

• terbutaline
Epidiolex (cannabidiol (CBD))

+

terbutaline

1 interaction

Caution Advised

cannabidiol + terbutaline

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, terbutaline may decr. seizure threshold)

• tetrabenazine
Epidiolex (cannabidiol (CBD))

+

tetrabenazine

1 interaction

Caution Advised

cannabidiol + tetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Epidiolex (cannabidiol (CBD))

+

thiotepa

1 interaction

Caution Advised

cannabidiol + thiotepa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiotepa may decr. seizure threshold)

• tiagabine
Epidiolex (cannabidiol (CBD))

+

tiagabine

1 interaction

Caution Advised

cannabidiol + tiagabine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ticagrelor
Epidiolex (cannabidiol (CBD))

+

ticagrelor

1 interaction

Caution Advised

cannabidiol + ticagrelor

caution advised: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• tinidazole
Epidiolex (cannabidiol (CBD))

+

tinidazole

1 interaction

Caution Advised

cannabidiol + tinidazole

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, tinidazole may decr. seizure threshold)

• tipranavir
Epidiolex (cannabidiol (CBD))

+

tipranavir

1 interaction

Caution Advised

cannabidiol + tipranavir

caution advised: combo may decr. cannabidiol levels, efficacy; may incr. tipranavir levels, risk of adverse effects (hepatic metab. induced; gut P-gp-mediated transport inhibited)

• tisagenlecleucel
Epidiolex (cannabidiol (CBD))

+

tisagenlecleucel

1 interaction

Caution Advised

cannabidiol + tisagenlecleucel

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, tisagenlecleucel may decr. seizure threshold)

• tolcapone
Epidiolex (cannabidiol (CBD))

+

tolcapone

1 interaction

Caution Advised

cannabidiol + tolcapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Epidiolex (cannabidiol (CBD))

+

tolterodine

1 interaction

Caution Advised

cannabidiol + tolterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolvaptan
Epidiolex (cannabidiol (CBD))

+

tolvaptan

1 interaction

Caution Advised

cannabidiol + tolvaptan

caution advised: combo may incr. tolvaptan levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• topiramate
Epidiolex (cannabidiol (CBD))

+

topiramate

1 interaction

Caution Advised

cannabidiol + topiramate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tranexamic acid
Epidiolex (cannabidiol (CBD))

+

tranexamic acid

1 interaction

Caution Advised

cannabidiol + tranexamic acid

caution advised, especially w/ high-dose IV tranexamic acid: combo may alter seizure control (antagonistic effects, tranexamic acid may decr. seizure threshold)

• trazodone
Epidiolex (cannabidiol (CBD))

+

trazodone

1 interaction

Caution Advised

cannabidiol + trazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• treosulfan
Epidiolex (cannabidiol (CBD))

+

treosulfan

1 interaction

Caution Advised

cannabidiol + treosulfan

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, treosulfan may decr. seizure threshold)

• triamcinolone
Epidiolex (cannabidiol (CBD))

+

triamcinolone

1 interaction

Caution Advised

cannabidiol + triamcinolone

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, triamcinolone may decr. seizure threshold)

• trifluoperazine
Epidiolex (cannabidiol (CBD))

+

trifluoperazine

1 interaction

Caution Advised

cannabidiol + trifluoperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, trifluoperazine may decr. seizure threshold)

• trihexyphenidyl
Epidiolex (cannabidiol (CBD))

+

trihexyphenidyl

1 interaction

Caution Advised

cannabidiol + trihexyphenidyl

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimethobenzamide
Epidiolex (cannabidiol (CBD))

+

trimethobenzamide

1 interaction

Caution Advised

cannabidiol + trimethobenzamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Epidiolex (cannabidiol (CBD))

+

trimipramine

1 interaction

Caution Advised

cannabidiol + trimipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, trimipramine may decr. seizure threshold)

• triprolidine
Epidiolex (cannabidiol (CBD))

+

triprolidine

1 interaction

Caution Advised

cannabidiol + triprolidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triptorelin
Epidiolex (cannabidiol (CBD))

+

triptorelin

1 interaction

Caution Advised

cannabidiol + triptorelin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, triptorelin may decr. seizure threshold)

• trospium
Epidiolex (cannabidiol (CBD))

+

trospium

1 interaction

Caution Advised

cannabidiol + trospium

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vadadustat
Epidiolex (cannabidiol (CBD))

+

vadadustat

1 interaction

Caution Advised

cannabidiol + vadadustat

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, vadadustat may decr. seizure threshold)

• valacyclovir
Epidiolex (cannabidiol (CBD))

+

valacyclovir

1 interaction

Caution Advised

cannabidiol + valacyclovir

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, acyclovir may decr. seizure threshold)

• valbenazine
Epidiolex (cannabidiol (CBD))

+

valbenazine

1 interaction

Caution Advised

cannabidiol + valbenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Epidiolex (cannabidiol (CBD))

+

valerian

1 interaction

Caution Advised

cannabidiol + valerian

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valganciclovir
Epidiolex (cannabidiol (CBD))

+

valganciclovir

1 interaction

Caution Advised

cannabidiol + valganciclovir

caution advised if seizure disorder use: combo may alter seizure control (valganciclovir converted to ganciclovir; antagonistic effects, ganciclovir may decr. seizure threshold)

• varenicline
Epidiolex (cannabidiol (CBD))

+

varenicline

1 interaction

Caution Advised

cannabidiol + varenicline

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, varenicline may decr. seizure threshold)

• velpatasvir
Epidiolex (cannabidiol (CBD))

+

velpatasvir

1 interaction

Caution Advised

cannabidiol + velpatasvir

caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metab. possibly induced)

• venlafaxine
Epidiolex (cannabidiol (CBD))

+

venlafaxine

1 interaction

Caution Advised

cannabidiol + venlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, venlafaxine may decr. seizure threshold)

• vigabatrin
Epidiolex (cannabidiol (CBD))

+

vigabatrin

1 interaction

Caution Advised

cannabidiol + vigabatrin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vilazodone
Epidiolex (cannabidiol (CBD))

+

vilazodone

1 interaction

Caution Advised

cannabidiol + vilazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, vilazodone may decr. seizure threshold)

• viloxazine
Epidiolex (cannabidiol (CBD))

+

viloxazine

1 interaction

Caution Advised

cannabidiol + viloxazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vorasidenib
Epidiolex (cannabidiol (CBD))

+

vorasidenib

1 interaction

Caution Advised

cannabidiol + vorasidenib

caution advised: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metab. inhibited)

• zidovudine
Epidiolex (cannabidiol (CBD))

+

zidovudine

1 interaction

Caution Advised

cannabidiol + zidovudine

caution advised: combo may incr. zidovudine levels, risk of adverse effects (UGT possibly inhibited)

• ziprasidone
Epidiolex (cannabidiol (CBD))

+

ziprasidone

1 interaction

Caution Advised

cannabidiol + ziprasidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ziprasidone may decr. seizure threshold)

• zolmitriptan
Epidiolex (cannabidiol (CBD))

+

zolmitriptan

1 interaction

Caution Advised

cannabidiol + zolmitriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Epidiolex (cannabidiol (CBD))

+

zonisamide

1 interaction

Caution Advised

cannabidiol + zonisamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)